Tavio Capital’s Amicus Therapeutics FOLD Stock Holding History

Tavio Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-355,785	Closed	-$4.84M	–	11
2019 Q1	$4.84M	Hold	355,785	–	–	1.78%	11
2018 Q4	$3.41M	Sell	355,785 -47,170	-12%	-$519K	1.42%	14
2018 Q3	$4.87M	Hold	402,955	–	–	1.9%	17
2018 Q2	$6.29M	Buy	+402,955	New	+$6.09M	2.13%	16

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Tavio Capital's FOLD Position: Q2 2019 in Review

Tavio Capital sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 355,785 shares — an estimated $4.84M sold.

Tavio Capital first reported a position in FOLD in Q2 2018 and held it in 4 quarters. The position peaked at $6.29M in Q2 2018. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

Tavio Capital reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
Tavio Capital sold 355,785 Amicus Therapeutics shares in Q2 2019, an estimated $4.84M.
Tavio Capital first reported a position in Amicus Therapeutics in Q2 2018 and held it in 4 quarters.
Tavio Capital's Amicus Therapeutics position peaked at $6.29M in Q2 2018.
206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on Tavio Capital's 13F filing for Q2 2019, filed 13 Aug 2019.